Re-treatment with SLT after initial treatment failure does not reduce IOP

Article

Two treatments with selective laser trabeculoplasty (SLT) in the same area of the trabecular meshwork (TM) do not significantly affect IOP, compared with two SLT treatments in differing areas, according to a recently published study.

Two treatments with selective laser trabeculoplasty (SLT) in the same area of the trabecular meshwork (TM) do not significantly affect IOP, compared with two SLT treatments in differing areas, according to a recent study published in Graefe's Archive for Clinical and Experimental Ophthalmology.

For this prospective, randomized clinical trial, patients with primary open-angle or pseudoexfoliation glaucoma were initially treated with SLT over 180° in the lower half of the trabecular meshwork (SLT 1). A total of 40 patients chosen for re-treatment with SLT were included in the study, and were randomized to either SLT 2 in the same, previously treated area of the TM, or to SLT 2 in the upper untreated area of the TM. IOPs were measured at pre-treatment, 2 hours, 1 month, 3 months and 6 months after SLT 2.

At baseline, no significant between-group differences existed in age, gender, pseudoexfoliation, glaucoma, time between SLT 1 and SLT 2, IOP before SLT, or IOP before SLT 2. After the study was completed, there were no significant differences in IOP between the groups after SLT 2 at 2 hours (t-test, P = 0.65), 1 month (t-test, P = 0.60), 3 months (t-test, P = 0.42), or 6 months (t-test, P = 0.66).

To access this study, go to the journal's website here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.